secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001390478-24-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Q3 net loss narrows to $7.1M; Phase 3 AML interim analysis on track for Q4 2024
--------------------------------------------------------------------------------

- Q3 net loss $7.1M ($0.10/sh) vs $9.3M ($0.33/sh) in Q3 2023; cash $21M.
- Phase 3 REGAL (GPS) in AML: interim analysis of 60 events on track for Q4 2024.
- FDA granted Rare Pediatric Disease Designation (RPDD) to GPS for pediatric AML.
- SLS009 Phase 2a data in r/r AML to be presented at ASH Dec 8; 31% overall response.
- R&D expenses $4.4M (-24% YoY); G&A expenses $3.0M (-14% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/0001390478-24-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001390478-24-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer